Clinical Report: Evaluation of Peer Referral Strategies in Digital Weight Loss Program

Overview

This study evaluates the impact of peer referral strategies on adherence and weight loss outcomes in a digital weight loss program utilizing tirzepatide.

Background

Obesity is a significant public health concern associated with increased risks of chronic diseases such as type 2 diabetes and cardiovascular conditions. The use of GLP-1 receptor agonists, including tirzepatide, has been recognized as a treatment strategy for obesity.

Data Highlights

The source material describes an evaluation of peer referral strategies in a digital weight loss program using tirzepatide. It does not provide numerical results, sample sizes, or specific effect estimates. Adherence was assessed using medication fulfillment and verified weight entries at 6 months, and propensity score matching was used to examine the independent association between peer referral and weight loss.

Key Findings

• Peer referral strategies were assessed for their effect on adherence and weight loss outcomes in a digital weight loss program.

• Adherence was operationally defined by medication fulfillment and verified weight entries at 6 months.

• Patients referred to the program showed different persistence rates compared to non-referred patients.

• The study utilized propensity score matching to analyze the independent effect of peer referral on weight loss.

Clinical Implications

The findings indicate that peer referral strategies were assessed for their effect on adherence to weight loss programs utilizing tirzepatide.

Conclusion

This analysis presents findings on peer referral strategies in digital weight loss programs.

Related Resources & Content

1. Aronne LJ, Sattar N, Horn DB, et al., JAMA, 2024 -- Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial.

2. Hankosky ER, Chinthammit C, Meeks A, et al., Diabetes Obes Metab, 2025 -- Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes.

3. Talay L, Hom J, Scott T, Ahuja N, Diabetes Obes Metab, 2026 -- Effectiveness and adherence in a tirzepatide-supported digital weight-loss programme in Australia.

4. the new gastroenterologist — Tirzepatide outperforms semaglutide for weight loss

5. MDSpire News — How Hormones May Influence Tirzepatide Outcomes

6. FDA Approves New Medication for Chronic Weight Management

7. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes–2026

8. Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity | Diabetes, Obesity, and Cardiometabolic CARE | American Diabetes Association

9. American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease – 2025 Update - Endocrine Practice

10. Practice guide on obesity, weight management, education, and resources - American Gastroenterological Association

11. Tirzepatide Once Weekly for the Treatment of Obesity | New England Journal of Medicine

12. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial - PMC

13. Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta‐Analysis of Head‐to‐Head Studies - Paccola - 2026 - Clinical Obesity - Wiley Online Library

14. Real-world 6-month persistence, adherence, and effectiveness of GLP-1 medications for overweight and obesity in a Medicaid population | Journal of Managed Care & Specialty Pharmacy

15. Journal of Medical Internet Research - Digital Engagement Significantly Enhances Weight Loss Outcomes in Adults With Obesity Treated With Tirzepatide: Retrospective Cohort Study of a Digital Weight Loss Service